The American Journal of Managed Care

Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow Considerations

This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
MedPage Today

Subcutaneous Alzheimer's Drug May Be on the Horizon

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...
Healio

Positive results in lung cancer show benefits of subcutaneous bispecifics

Please provide your email address to receive an email when new articles are posted on . Subcutaneous delivery reduced administration time from several hours to less than 5 minutes. Although unexpected ...
Nasdaq

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with ...

ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...
Healio

Subcutaneous chemotherapy for solid tumors nets FDA approval

Please provide your email address to receive an email when new articles are posted on . The subcutaneous pembrolizumab combination was approved for adults and ...

Subcutaneous RYBREVANT® (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
Renal & Urology News

Subcutaneous Nivolumab Shows ‘Clinical Equipoise’ With IV Dosing in mRCC

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
The American Journal of Managed Care

Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...
Monthly Prescribing Reference

About One-Third of Professionals Prescribe Subcutaneous Contraceptive for Self-Administration

Many professionals report awareness, but few actively prescribe the self-administered injectable contraceptive DMPA. HealthDay News — About one-third of health care professionals who are aware of ...